Organon touts late-stage data for sugammadex

Organon says that its experimental anesthesia drug sugammadex was nine to 12 times better than standard therapy in reversing muscular block from anesthesia. The Phase III data compared sugammadex with neostigmine. "In the clinical trials until now sugammadex has generally demonstrated the ability to reverse shallow and profound depths of rocuronium-induced neuromuscular blockade within three minutes," Organon said. Organon--a subsidiary of Akzo Nobel--estimates the size of the market as more than half a billion dollars a year.

- check out the release for more information

Related Articles:
Organon buyout raises questions about pipeline. Report
Pfizer bails out on collaboration with Organon. Report